BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease (AD) Blocking the collagen receptor GP6 could treat Alzheimer’s disease by reducing platelet-associate β amyloid aggregation. In vitro, platelets...
BioCentury | May 6, 2019
Distillery Therapeutics

AGTR1 inhibitor nanoconjugate boosts chemo, immunotherapies in cancers

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer; breast cancer Mouse studies suggest a nanoconjugate based on the generic ATGR1 inhibitor valsartan could enhanced the efficacy of chemotherapies and checkpoint inhibitors in pancreatic and metastatic breast cancers....
BioCentury | Mar 30, 2018
Product Development

Perception into pain

...Ltd. used ACTTION’s recommendations in a Phase II postherpetic neuralgia trial of olodanrigan (EMA401), an angiotensin II type 2...
...placebo-controlled phenotype-stratified study.” Pain (2014) Rice, A., et al. “EMA401, an orally administered highly selective angiotensin II type 2...
BioCentury | Feb 22, 2018

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
BioCentury | Jan 25, 2018
Company News

Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday. Spark will receive $105 million up front and...
BioCentury | Jan 5, 2018
Clinical News

FDA approves Prexxartan to treat hypertension

Medicure Inc. (TSX-V:MPH; PINK:MCUJF) said FDA granted final approval to an NDA from Carmel Biosciences Inc. (Atlanta, Ga.) for Prexxartan valsartan oral solution to treat hypertension in patients ages six and older, heart failure and...
BioCentury | Dec 13, 2017
Distillery Therapeutics


INDICATION: Renal damage Cell culture and rat studies identified a benzimidazole-based TRPC5 inhibitor that could help treat focal segmental glomerulosclerosis (FSGS). Chemical synthesis and testing in HEK cell-based ion channel activity assays of a library...
BioCentury | Nov 22, 2017
Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
BioCentury | Jun 22, 2017
Clinical News

Novartis' canakinumab cuts CV risk in MI patients

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab ( ACZ885 ) plus standard of care reduced cardiovascular risk in patients with a prior heart attack and inflammatory atherosclerosis in the Phase III CANTOS trial. The mAb against IL-1 beta...
BioCentury | Apr 25, 2017
Company News

Novartis confident in 2017 Entresto goal

Novartis AG (NYSE:NVS; SIX:NOVN) believes sales of heart failure drug Entresto sacubitril/valsartan can reach the company's $500 million goal this year, although the company's 1Q17 earnings report released Tuesday said sales were $84 million for...
Items per page:
1 - 10 of 190